<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581789</url>
  </required_header>
  <id_info>
    <org_study_id>H-2007-0063</org_study_id>
    <secondary_id>CO05507</secondary_id>
    <nct_id>NCT00581789</nct_id>
  </id_info>
  <brief_title>Erlotinib and Sunitinib in NSCLC</brief_title>
  <official_title>Phase I Study of Erlotinib and Sunitinib in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in
           patients with non-small cell lung cancer (NSCLC).

        -  To determine response to sunitinib plus erlotinib in patients with non-small cell lung
           cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib, sunitinib</intervention_name>
    <description>erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Sutent</other_name>
    <other_name>SU011248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven stage IIIB (with pleural effusion or
             pericardial effusion) or IV (either primary or recurrent) NSCLC (except squamous cell
             histology).

          -  Measurable disease per RECIST

          -  Life expectancy of at least 12 weeks.

          -  Adequate bone marrow, hepatic and renal function

          -  ECOG performance status 0, 1 or 2.

          -  One and only one prior treatment with a chemotherapy regimen, including a platinum
             based regimen for advanced disease (Stage IIIB with malignant effusion or Stage IV).

          -  Signed and dated informed consent document indicating that the patient (or legally
             acceptable representative) has been informed of all pertinent aspects of the trial
             prior to enrollment.

          -  Female patients must be surgically sterile, postmenopausal or agree to use effective
             contraception during the period of therapy. Male patients must be surgically sterile
             or agree to use effective contraception during the period of therapy.

        Exclusion Criteria:

          -  Squamous cell histology.

          -  History of untreated brain metastases

          -  Prior treatment with &gt;1 systemic chemotherapy-based regimens for advanced disease
             (Stage IIIB with malignant effusion or Stage IV).

          -  Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitors, or
             other angiogenic inhibitors (including but not limited to bevacizumab, sunitinib,
             erlotinib, gefitinib, or thalidomide).

          -  Prior chemotherapy, radiation therapy, surgery, or investigational agent within 4
             weeks prior to study entry, except palliative radiation therapy to a non-target
             lesions (must have been completed 2 weeks prior to study enrollment).

          -  Eligibility of patients receiving any medications or substances known to induce or
             inhibit CYP3A4 and /or with the potential to affect the activity or pharmacokinetics
             of sunitinib or erlotinib will be determined following review of their case by the
             Principal Investigator.

          -  NCI CTCAE grade 3 hemorrhage within 4 weeks of starting therapy.

          -  Ongoing treatment with warfarin

          -  Prior treatment with high-dose chemotherapy requiring stem cell rescue.

          -  Prior irradiation to &gt;25% of the bone marrow (whole pelvis = 25%).

          -  Diagnosis within prior 3 years of second malignancy, except basal cell carcinoma,
             squamous cell skin carcinoma or in situ carcinoma that has been completely treated
             without evidence of recurrent disease for 12 months.

          -  Current treatment on another therapeutic clinical trial or receipt of another
             investigative agent within 4 weeks of study entry.

          -  Any of the following within 12 months prior to starting study treatment: myocardial
             infarction, unstable angina, coronary/peripheral artery bypass graft, congestive heart
             failure, cerebrovascular accident including transient ischemic attack, or pulmonary
             embolus.

          -  Hypertension (&gt;150/100mmHg) that cannot be controlled with standard antihypertensive
             agents.

          -  Ongoing cardiac dysrhythmias of grade &gt;2, â‰¥ grade 3 atrial fibrillation, or QTc
             interval of &gt;450 msec for males and &gt;470 msec for females.

          -  Evidence of hemoptysis &lt;4 weeks of starting study treatment.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality

          -  HIV-positive patients

          -  Women who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Traynor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <last_update_submitted>February 10, 2012</last_update_submitted>
  <last_update_submitted_qc>February 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non small cell lung cancer</keyword>
  <keyword>sunitinib</keyword>
  <keyword>erlotinib</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

